Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; mannitol; water for injections; hydrochloric acid; sodium hydroxide - as prescribed by the doctor, cisplatin is used as palliative treatment either in association with other therapies or in combination with other forms of chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin is indicated for the treatment of: metastatic non-seminomatous germ cell carcinoma advanced and refractory carcinoma of the ovary; advanced and refractory carcinoma of the bladder; squamous cell carcinoma of the head and the neck.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin is used as palliative treatment either in association with other therapies or in combination with other forms of chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin is indicated in metastatic, non seminomatous germ cell carcinoma, advanced stage and refractory ovarian carcinoma, advanced stages of refractory bladder carcinoma, advanced stages of refractory bladder carcinoma and squamous cell carcinoma of the head and neck. cisplatin is indicated in combination with other antineoplastic agents for the treatment of metastatic testicular tumors.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin is indicated for the treatment of: metastatic carcinoma of non-seminoma germinale cells, advanced and refractory carcinoma of the ovary, advanced and refractory carcinoma of the bladder, epidemiological carcinoma of the head and the neck.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin injection is indicated for the treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - cisplatin sterile concentrate is an anti-cancer medicine in the form of a concentrate for infusion. cisplatin is used in the treatment of certain types of cancer, for example ovarian cancer, testicular cancer, bladder cancer and head and neck cancer. cisplatin may be used in combination with other anti-cancer medicines.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid; peg-35 castor oil; ethanol absolute - paclitaxel is used in the treatment of a number of types of cancer including ovarian cancer, breast cancer, and advanced non-small cell lung cancer. it is also used in aids-related kaposi's sarcoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - ovarian cancer: ??in first-line chemotherapy paclitaxel is indicated for the treatment of patients with advanced disease or a residual disease (>1 cm) after initial laparotomy, in combination with cisplatin. ??in second-line chemotherapy paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy. breast cancer: ??in the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (ac) therapy. adjuvant treatment with paclitaxel should be regarded as an alternative to extended ac therapy. ??paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (her-2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. ??as a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate, or relapse within 6 months of adjuvant chemotherapy. advanced non-small cell lung cancer (nsclc): ??paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy. aids-related kaposi?s sarcoma (ks): ??paclitaxel is indicated for the treatment of patients with advanced aids-related ks who have failed prior liposomal anthracycline therapy.